Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 27

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 27
---
 meaning of the Securities Act, and the compensation
of Jones will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jones against certain civil liabilities,
including liabilities under the Securities Act. We have also agreed to contribute to payments Jones may be required to make in respect
of such liabilities.

The offering of shares of our common stock pursuant
to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. We and Jones may each terminate
the Sales Agreement at any time upon three days’ prior notice.

This summary of the material provisions of the
Sales Agreement does not purport to be a complete statement of its terms and conditions.

Jones and its affiliates may in the future provide
various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services
they may in the future receive customary fees. In the course of its business, Jones may actively trade our securities for its own account
or for the accounts of customers, and, accordingly, Jones may at any time hold long or short positions in such securities.

<div align='center'>S-20</div>

This prospectus supplement and the accompanying
base prospectus in electronic format may be made available on a website maintained by Jones, and Jones may distribute the prospectus supplement
and the accompanying base prospectus electronically.

<div align='center'>S-21

LEGAL MATTERS</div>

The validity of the issuance of the common
stock offered by this prospectus supplement will be passed upon for us by Ballard Spahr
LLP, Seattle, Washington. Jones is being represented in connection with this offering by Sichenzia Ross Ference Carmel LLP, New
York, New York.

<div align='center'>EXPERTS</div>

Ernst & Young LLP, independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise
substantial doubt about Armata Pharmaceuticals, Inc.’s ability to continue as a going concern as described in Note 2 to the
consolidated financial statements) which is incorporated by reference in this prospectus supplement. Our consolidated financial statements
are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting
and auditing.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We